Company Filing History:
Years Active: 2025
Title: Innovations by Fernando Garces in Cardiovascular Treatment
Introduction
Fernando Garces is an accomplished inventor based in San Mateo, CA (US). He has made significant contributions to the field of medicine, particularly in the development of treatments for cardiovascular diseases. His innovative work has led to the creation of a patent that addresses critical health issues.
Latest Patents
Fernando Garces holds a patent for "Anti-ASGR-1 monoclonal inhibitory antibodies." This patent describes antigen binding proteins that interact with ASGR, ASGR-1, and/or ASGR-2. The patent outlines methods for making and using these proteins, which are essential in treating and preventing cardiovascular disease. Additionally, it includes methods for administering pharmaceutically effective amounts of interfering RNA compositions that reduce the expression of ASGR, ASGR-1, and/or ASGR-2. He has 1 patent to his name.
Career Highlights
Garces is currently associated with Amgen Inc., a leading biotechnology company. His work at Amgen has allowed him to focus on innovative solutions that can significantly impact patient care and treatment outcomes. His dedication to research and development has positioned him as a key player in the field of cardiovascular health.
Collaborations
Throughout his career, Fernando has collaborated with notable colleagues, including Paul Nioi and Peter Coward. These collaborations have fostered an environment of innovation and have contributed to the advancement of medical treatments.
Conclusion
Fernando Garces is a prominent inventor whose work in developing treatments for cardiovascular diseases showcases his commitment to improving healthcare. His patent on Anti-ASGR-1 monoclonal inhibitory antibodies represents a significant advancement in medical science.